



Oklahoma City Office
10429 West Reno Avenue, Suite 100
Oklahoma City, OK 73127
Tulsa Office
7136 South Yale Avenue, Suite 300
Tulsa, OK 74136
Phone: 405-440-2095
Private Mobile: 405-738-9913
Email: LeslieW@rheahealth.com

INDEPENDENT MEDICAL EXAMINATION

RECORD / PEER REVIEW REPORT

Prepared in accordance with AMA Guides to the Evaluation of Permanent Impairment, 6th Edition, where applicable

Claimant:	
Date of Birth / Age at DOI:	/ 69 years old
Date of Injury / Loss:	8/23/2025
Date of Report:	8/5/2026
Claim / File Number(s):	Claim No. () / File # / Physician File #
Jurisdiction / Line of Coverage:	Oklahoma; automobile / medical payments (No-Fault/med-pay) claim
Referral Source:	, , on behalf of (Adjuster:)
Type of Review:	Records/peer review only — no examinee was seen
Examining/ Reviewing Physician:	Leslie Welch, D.C., CICE, NRCME

[illegible]

I. Purpose, Scope, and Methodology of Review.....	3
II. Records Reviewed	3
III. Case Snapshot / Identifying Information	4
IV. Chronological Medical Summary.....	4
V. Documentation Observations (Factual / Pattern-Level)	11
VI. Applicable Standards, Guidelines, and Literature	13
VII. Causation Analysis.....	14
VIII. Reasonableness and Necessity of Duration, Frequency, and Type of Care	17
IX. Modality-Specific Analysis	19
X. Open Items / Limitations of the Current Record.....	21
XI. Response to Specific Referral Questions	22
XII. Impairment Rating (AMA Guides, 6th Edition)	24
XIII. Summary of Opinions	24
XIV. Limitations, Disclosures, and Certification	25
Appendix C — Cited Literature	26

III. Case Snapshot / Identifying Information

IV. Chronological Medical Summary

IV.A — Mechanism of Injury (Per Incident/Police Report)

5 of 29

The chiropractic intake history records the claimant’s self-reported estimate of impact speed as “35–45 mph.” The police report does not independently document vehicle speed, EDR data, or accident-reconstruction findings, and the officer’s narrative — claimant “slowing for traffic stopped at the light,” struck from behind — together with the property-damage narrative describing “minor damage” to both vehicles, is more consistent with a lower-speed, congested-traffic rear-end impact. This discrepancy between the uncorroborated self-reported speed estimate and the objective accident record is addressed further in Section VII.B (Mechanism Plausibility).

The claimant was evaluated at [REDACTED] Trauma Emergency on 8/23/2025 by [REDACTED], MD (arrival 1332; discharge 1534). Chief complaint: motor vehicle crash, headache, nausea. Vitals were notable for elevated blood pressure (170/94), with pulse 69, temperature 98.2°F, respirations 18, and SpO2 95%. Physical examination was largely benign: no acute distress; normocephalic/atraumatic; neck supple with no midline cervical spine tenderness to palpation; no seatbelt sign on chest or abdomen; abdomen soft and non-tender; neurologically intact with no focal deficit; alert and oriented x3; mood and behavior normal.

In the ER, the claimant received ondansetron (Zofran-ODT) 4 mg PO, ibuprofen (Advil/Motrin) 800 mg PO, and ketorolac tromethamine (Toradol) 30 mg, and was discharged with a new prescription for methocarbamol (Robaxin) 500 mg PO three times daily as needed for muscle spasm, for up to five days. Diagnoses assigned were MVC, initial encounter (V87.7XXA) and headache (R51.9); disposition was discharge home, condition documented as “improved.” Follow-up was recommended with [REDACTED], MD (Family Medicine) in approximately one week (around 8/30/2025), “as needed,” and a return to [REDACTED] if symptoms worsened.

Medication	Common Name	Class / Purpose
Methocarbamol 500 mg (new, started at ER discharge)	Robaxin	Muscle relaxant — PRN, up to 5 days
Acyclovir 400 mg	Zovirax	Antiviral
Albuterol HFA 108mcg inhaler	ProAir / Proventil / Ventolin	Bronchodilator
Alendronate 70 mg	Fosamax	Osteoporosis (bisphosphonate)
Aspirin 81 mg	Low-dose aspirin	Cardiac/stroke prophylaxis
Atorvastatin 40 mg	Lipitor	Cholesterol
Estradiol 0.1mg/gm vaginal cream	Estrace	Hormone
Fexofenadine 180 mg	Allegra	Antihistamine/allergy
Fish oil 1000 mg	—	Supplement
Fluticasone-vilanterol 100-25mcg inhaler	Breo Ellipta	Asthma/COPD
Glucosamine Chondroitin Complex	—	Supplement
Lisinopril-hydrochlorothiazide 20-12.5 mg	Prinzide / Zestoretic	Blood pressure
Methylprednisolone 4 mg	Medrol Pak	Steroid
Montelukast 10 mg	Singulair	Asthma/allergy
Paroxetine 20 mg	Paxil	Antidepressant (SSRI)
Phentermine-Topiramate ER 3.75-23 mg	Qsymia	Weight management
Systane Complete 0.6%	—	Ophthalmic (eye drops)
Vitamin D3 25mcg (1000 IU)	Cholecalciferol	Supplement
Zinc 50 mg	—	Supplement

7 of 29

- Initial treatment plan:**

- ### Visit-by-Visit / Serial Treatment Trend Table

Date	Visit Type	N ec k	Lo w Ba ck	He ad ac he	Di zz y	Hi p	Sh ou ld er	Modalities Billed
8/29/25	Initial Hx/Exam	7	7	7	7	7 (R hip)	7	CMT, myofascial, muscle stim, US
9/02/25	Daily Note	7	7	7	7	7	7	CMT, myofascial, muscle stim
9/03/25	Daily Note	7	7	6	7	7	7	CMT, US, muscle stim
9/05/25	Daily Note	7	7	6	7	7	7	CMT, myofascial, muscle stim
9/08/25	Daily Note	7	7	5	7	7	6	CMT, US, muscle stim
9/10/25	Daily Note	7	7	4	7	7	6	CMT, US, muscle stim
9/12/25	Daily Note	7	7	4	5	5	6	CMT, US, muscle stim
9/15/25	Daily Note	7	7	4	5	5	6	CMT, myofascial, muscle stim
9/17/25	Daily Note	7	6	4	5	4	6	CMT, myofascial, muscle stim

		N	Lo	He	Di		Sh	
Date	Visit Type	ec	w	ad	zz	Hi	ou	Modalities Billed
9/19/25	Daily Note	7	6	4	5	4	6	CMT, myofascial, muscle stim
9/22/25	Daily Note	7	6	4	5	5	5	CMT, myofascial, muscle stim
9/24/25	Daily Note	7	6	5	6	6	4	CMT, myofascial, muscle stim, US, + Alpha-Stim (NEW)
10/01/25	Daily Note	7	7	6	6	6	4	CMT, myofascial, muscle stim, Alpha-Stim
10/06/25	Daily Note	7	7	6	6	6	4	CMT, myofascial, muscle stim, Alpha-Stim
10/08/25	Daily Note	5	6	5	5	6	4	CMT, myofascial, muscle stim, Alpha-Stim
10/10/25	Daily Note	4	5	5	4	6	3	CMT, US, muscle stim, Alpha-Stim
10/13/25	Daily Note	5	6	5	4	6	3	CMT, myofascial, muscle stim, Alpha-Stim
10/16/25	Daily Note	4	5	4	3	5	3	CMT, myofascial, US, muscle stim, Alpha-Stim
10/20/25	Daily Note	4	5	4	3	5	3	CMT, myofascial, muscle stim, Alpha-Stim
10/23/25	Daily Note	3	4	4	3	4	3	CMT, myofascial, muscle stim, Alpha-Stim
10/27/25	Daily Note	3	4	4	3	4	2	CMT, US, muscle stim, Alpha-Stim
10/30/25	Daily Note	3*	4*	5	3	4	2	CMT, US, muscle stim, Alpha-Stim
11/03/25	Daily Note	3	4*	5	3	4	2	CMT, US, muscle stim, Alpha-Stim
11/06/25	Daily Note	3	4*	5	3	4	2	CMT, US, muscle stim, Alpha-Stim
11/10/25	Daily Note	3	4*	4*	3*	4*	2*	CMT, US, muscle stim, Alpha-Stim
11/12/25	Daily Note	3	4*	4	3	4	2	CMT, US, muscle stim, Alpha-Stim
11/17/25	Daily Note	3	4	3-4	3	4	2	CMT, myofascial, US, muscle stim, Alpha-Stim
11/20/25	Daily Note	3	4*	3-4	2	4	2	CMT, myofascial, muscle stim, Alpha-Stim

Date	Visit Type	N ec k	Lo w Ba ck	He ad ac he	Di zz y	Hi p	Sh ou ld er	Modalities Billed
11/24/25	Daily Note	3	4*	3	2	4	2	CMT, US, muscle stim, Alpha-Stim
12/05/25	Daily Note (post-Thanksgiving)	3	4*	3	1-2	4	2	CMT, US, muscle stim, Alpha-Stim
12/09/25	Daily Note	3	4*	3	1-2	3	1-2	CMT, US, muscle stim, Alpha-Stim
12/12/25	Daily Note	3	4*	3	1-2	3	1-2	CMT, US, muscle stim, Alpha-Stim
12/15/25	Daily Note	3*	4*	3	1	3	1-2	CMT, US, muscle stim, Alpha-Stim
12/18/25	Daily Note	3*	4*	3	1	3	1	CMT, US, muscle stim, Alpha-Stim
12/30/25	Daily Note (final visit in file, post-holidays)	3	4	4	1	4	1	CMT, US, muscle stim, Alpha-Stim

Chart Interpretation

- Visits 1–11 (8/29/2025–9/22/2025, approximately 3.5 weeks): Neck, low back, dizziness, hip, and shoulder pain ratings remain at 6–7/10 throughout this period. Headache is the only complaint to decline in this span, from 7/10 to 4/10.
- Visit 11 (9/24/2025): Alpha-Stim/microcurrent therapy is added to the treatment plan. No cervical or lumbar range-of-motion measurements or orthopedic tests are re-administered at this visit or at any subsequent visit in the file.
- Visits 12–20 (10/1/2025–10/23/2025, approximately 4.5 weeks): Pain ratings decline gradually across most complaints — neck pain from 7/10 to 3/10, low back pain from 7/10 to 4/10, dizziness from 6/10 to 3/10, and shoulder pain from 4/10 to 3/10.
- Visits 21–35 (10/27/2025–12/30/2025, approximately 9.5 weeks): Pain ratings fluctuate within a narrow range for the remainder of the file — neck pain at 3/10, low back pain at 3–4/10 (no value below 3/10 is charted in this span), headache at 3–5/10, dizziness at 1–3/10, hip pain at 3–4/10 (no value below 2/10 is charted), and shoulder pain at 1–2/10. Values increase intermittently around 10/30/2025, 11/3/2025, and 12/5/2025 (post-Thanksgiving) and 12/30/2025 (post-December-holiday) before returning to the prior range. No visit in this span, or in the file overall after 8/29/2025, documents a numeric value of 0 for any complaint, and no

measurable improvement through the earlier portion of the treatment course before symptoms plateaued.

- Diagnosis list identical at all 35 visits. The same eight ICD-10 codes appear verbatim in every Initial History, Initial Exam, and all 34 Daily Notes from 8/29/2025 through 12/30/2025, without addition, subtraction, or resolution of any diagnosis over four months of care.
- No re-examination/re-assessment visit is documented anywhere in the file. Cervical and lumbar ROM measurements and orthopedic testing (Kemp's, straight leg raise, compression/distraction tests) were performed and charted only once, at the 8/29/2025 intake, and were never re-measured or re-administered at any of the subsequent 34 visits. Improvement after intake is documented only via subjective pain-scale narrative and general palpatory descriptors, not objective, reproducible measures.
- The Initial Examination note's "PLAN" section identifies the modalities to be used (chiropractic manipulation, myofascial release, ultrasound, muscle stimulation) but does not specify a defined number of visits, a prescribed visit frequency, or an anticipated treatment endpoint. No subsequent note in the file documents such a plan. However, the actual dates of service reflect a discernible, consistent day-of-week pattern: visits occurred on a Monday/Wednesday/Friday (three-times-weekly) schedule from approximately 9/8/2025 through 9/24/2025, then shifted to an approximately Monday/Thursday (twice-weekly) schedule from approximately 10/13/2025 through the remainder of care. No note in the file documents a reassessment, clinical rationale, or objective finding associated with this change in frequency.
- No formal discharge summary, maximum medical improvement (MMI)/plateau determination, or documented discussion of care-plan modification appears anywhere in the file, notwithstanding that symptom ratings plateaued (fluctuating 1-4/10, with intermittent increases) for the final approximately ten weeks of care (roughly 10/23/2025-12/30/2025).
- Hip-pain laterality is inconsistent in the chart. The initial 8/29/2025 exam and early visits document "Right Hip Pain" only; beginning around 10/16/2025 the same complaint is re-labeled "Right/Left Hip Pain" without any interval history explaining a new left-sided onset, trauma, or exacerbating event.
- No referral to any other provider (orthopedics, neurology, PM&R, pain management) is documented at any point in the four-month chiropractic course, notwithstanding persistent headache and dizziness complaints that the claimant had told the ER she was already separately being worked up for by an outside neurologist/allergist prior to the accident.
- No imaging beyond the 8/23/2025 ER CT (head and cervical spine, both without contrast) appears anywhere in the file. No MRI was obtained despite four months of persistent axial complaints and a plateau in symptom improvement.

- The chiropractic record does not reflect that any attempt was made to obtain records or prior imaging from the claimant's pre-existing outside neurology and allergy work-up. Given that this work-up was already underway for chronic headache symptoms at the time of the accident, it is reasonably likely that some form of prior neurological imaging exists from that work-up; no such prior imaging was requested or referenced at any point in the 35-visit chiropractic course.
- No X-rays or any other independent imaging were obtained by the chiropractor at intake or at any point during the 35-visit course. The Initial History note does not cite or reference the actual 8/23/2025 ER CT report; instead, it records the imaging results as relayed verbally by the claimant ("per claimant, no fractures/dislocations"). If the treating chiropractor independently obtained or reviewed the CT report itself, that review is not documented anywhere in the file; the chart as written reflects reliance on the claimant's verbal account alone. Chiropractic manipulation (CMT) was initiated at the first visit, 8/29/2025, on this basis.
- The claimant's home medication list, including alendronate (Fosamax) for osteoporosis, is documented in the ER After-Visit Summary (Section IV.B) but is not referenced, reconciled, or acknowledged anywhere in the 35-visit chiropractic record — notwithstanding its direct relevance to manipulation safety considerations at the cervical and lumbar levels treated.
- The claimant's ER blood pressure was elevated (170/94), and her home medication list includes lisinopril-hydrochlorothiazide for hypertension; this may reflect a situational elevation related to acute pain/trauma, a baseline control issue, or both, and is noted here as part of the complete medication and vital-sign picture rather than as an independent standard-of-care finding.
- Billing/coding discrepancy: the chiropractic billing ledger lists the 8/29/2025 visit as CPT 99202 (new-patient E/M, straightforward), while the narrative "PLAN" section of the Initial Examination note itself states "Consultation, history and examination, 99203" — a discrepancy between the ledger and the clinical note.

VI. Applicable Standards, Guidelines, and Literature

The chiropractic literature and guideline frameworks applicable to duration, frequency, and modality selection for this case's presentation (cervical and lumbar mechanical/soft-tissue pain of traumatic onset, with an adjunctive-modality question specific to headache and dizziness) are identified and fully cited in **Appendix C — Cited Literature**, attached to this report. The governing principle drawn from those sources is set forth below.

Payer/regulatory frameworks (e.g., Oklahoma workers’ compensation visit/duration parameters, cited in Section VIII.C) are referenced only as comparators on “typical” visit/duration patterns in a different line of coverage — not as the binding legal or clinical standard governing this Oklahoma automobile/med-pay claim.

With respect to the cervical spine specifically, and consistent with the 65%/35% apportionment set forth above, it is my opinion, to a reasonable degree of medical probability, that the claimant's pre-existing cervical degenerative disease — reflecting the uncovertebral and facet spurring, central canal stenosis at C5-6, and foraminal stenosis at C3-4 and C6-7 identified on the 8/23/2025 CT — necessarily developed over a period of years preceding the collision, and represents the predominant contributor to the claimant's ongoing cervical symptomatology. The acute cervical soft-tissue injury sustained in the collision is layered on top of that pre-existing degenerative foundation; its contribution is real and causally related to the incident, but proportionally smaller than that of the underlying degenerative disease. This relative weighting is consistent with, and lends further support to, the plateau pattern discussed in Section VIII.A: a claimant whose persistent cervical symptoms are substantially rooted in a chronic degenerative process would be expected to reach and sustain a stable, non-zero symptom plateau of the kind reflected in this chart, rather than progress toward full resolution, since the underlying degenerative pathology does not resolve with palliative chiropractic care.

The claimant's pre-existing, outside neurology and allergy work-up for chronic headaches — referenced in her own history to the ER — was not produced in this file. Full causal apportionment of the headache and dizziness complaints cannot be completed on the current record. Records from [REDACTED], MD, and from the claimant's outside neurologist and allergist, are not part of the current file and would bear materially on this gap if available (see Section X). It is my opinion that, given the claimant's pre-existing, active neurology work-up for chronic headaches, it is reasonably likely that some form of prior neurological imaging (e.g., brain MRI) exists from that work-up; such imaging, if obtained, would have provided a valuable pre-accident baseline against which the 8/23/2025 ER imaging could have been compared, and would materially assist the causation analysis for the headache and dizziness complaints if it becomes available. The interim opinion above is offered on the current record and is subject to revision should those records become available.

- The claimant's cervical spine complaint represents an aggravation — a permanent alteration of the natural history of her pre-existing cervical degenerative disease — causally related to the 8/23/2025 incident. The pre-existing degenerative disease, which necessarily developed over a period of years preceding the collision, is apportioned at approximately 65% and represents the predominant contributor to the claimant's ongoing cervical symptomatology; the acute cervical soft-tissue injury sustained in the collision, apportioned at approximately 35%, is layered on top of that pre-existing degenerative foundation and is a real, causally related, but

proportionally smaller contributor (Section VII.D). This is consistent with the claimant's persistent, non-zero cervical symptom plateau documented from late October 2025 through the final visit, for the reasons set forth in Sections VII.C, VII.D, and VIII.A.

- The claimant's thoracic complaint represents a new injury causally related to the 8/23/2025 incident.
- The claimant's lumbar complaint represents a new injury causally related to the 8/23/2025 incident.
- The claimant's left shoulder complaint represents a new injury causally related to the 8/23/2025 incident.
- The claimant's hip complaint represents a new injury causally related to the 8/23/2025 incident, subject to the laterality-documentation inconsistency noted in Section V.
- The claimant's headache and dizziness complaints cannot be causally apportioned between the 8/23/2025 incident and her pre-existing, independently-managed chronic headache condition on the current record; this opinion is offered on an interim basis and is subject to revision upon receipt of the outside neurology/allergy records identified in Section X.

VIII. Reasonableness and Necessity of Duration, Frequency, and Type of Care

VIII.A — Duration & Frequency

Applying the governing principle in Section VI to the chart findings in Section IV: eleven visits had already occurred by 9/24/2025 (approximately four weeks into care) with symptom ratings still largely unchanged from intake (6–7/10 across most complaints) — the point at which the guideline framework calls for reassessment and a plan-modification decision is precisely where no reassessment occurs in this chart, and instead a new modality (Alpha-Stim) was added without any documented re-examination. Objective improvement (ROM, orthopedic findings) was never re-measured after intake, so there is no objectively documented functional basis on which a guideline-consistent reassessment decision could have been made at the 6–12 visit mark, the 2–4 week mark, or at any later point in this record. This is consistent with the visit-frequency pattern identified in Section V: care proceeded on a consistent three-times-weekly schedule through late September 2025 and then shifted to a twice-weekly schedule from mid-October 2025 onward, with no note in the file documenting a reassessment, clinical rationale, or objective finding tied to that change in frequency.

The subjective pain trajectory — flat for approximately four weeks, then declining, then plateauing at 1-4/10 with fluctuation from late October through the December holidays —

The overall pattern — 35 visits over approximately 18 weeks with no documented reassessment, no change in the diagnosis list, and a care plan structurally identical (same modalities, same billing pattern) from visit 2 through visit 35 — is difficult to reconcile with the guideline principle that duration should be driven by documented clinical response rather than a default ongoing-visit pattern — notwithstanding that the manipulative care delivered throughout that period was, in isolation, technically consistent with standard practice.

No red-flag findings (progressive neurologic deficit, saddle anesthesia, bowel/bladder involvement, suspected fracture, infection, unexplained weight loss, major trauma beyond the MVC itself) are documented at any point, so an emergent referral was not clinically indicated on this record. However, the failure-to-progress referral threshold — assessed via standardized outcome measures at a therapeutically stable plateau — appears to have been reached by approximately visit 20 (10/23/2025), consistent with the plateau determination in Section VIII.A, and the commonly cited general orthopedic benchmark of a 4–6 week trial before specialist consultation (absent red flags) had already elapsed twice over by that point. No consultation or comanagement referral is documented anywhere in the four-month file, despite the plateau and despite headache/dizziness — the claimant’s most neurologically-flavored complaints — being the specific target of prolonged, unmodified adjunctive therapy rather than diagnostic escalation or referral. It is my opinion, to a reasonable degree of medical probability, that upon reaching this plateau at approximately visit 20, chiropractic treatment should have been discontinued or tapered, with referral or comanagement consideration undertaken at that point, rather than continuing the unmodified chiropractic care documented in this file for a further 15 visits through 12/30/2025.

20 of 29

IX.B — Alpha-Stim / MENS (Microcurrent) Therapy

In this case, Alpha-Stim was introduced on 9/24/2025 (visit 11 of 35) with the stated purpose of reducing the claimant's headaches and dizziness, and was then continued at every visit for the remainder of the course — 24 consecutive sessions — through 12/30/2025. The chart does not document the body region to which Alpha-Stim was actually applied (a cervical paraspinal/suboccipital application would at least be mechanistically plausible as an adjunct for a cervicogenic headache component; the notes do not specify), nor does it document objective findings correlating a cervicogenic mechanism to the claimant's headache pattern. No vestibular or positional workup was performed at any point to support a cervicogenic or otherwise treatable mechanism for the dizziness. Critically, the claimant's own pre-existing, independently-managed chronic headache work-up (with an outside neurologist and allergist) is never acknowledged or addressed anywhere in the chiropractic record, despite headache being one of the two specific complaints Alpha-Stim was directed at treating.

It is further my opinion that, because this differentiation was never undertaken, the referral point for the headache and dizziness complaints specifically is not the same as the musculoskeletal plateau point addressed in Sections VIII.A–VIII.B (approximately visit 20,

history and examination, 99203"; this discrepancy is unresolved on the current record.

- It is unknown to which body region Alpha-Stim/MENS was applied at each visit; the chart does not specify.

XI. Response to Specific Referral Questions

Question 1:

Based on the records from 8/29/2025 through 12/30/2025, was the overall course of chiropractic care medically necessary and appropriate under generally accepted chiropractic standards?

See Section VIII.A for the full analysis. In summary, the overall course of chiropractic care was reasonable and necessary during an initial period consistent with guideline-based therapeutic trial and reassessment expectations, but the record does not support that the full 35-visit, ~18-week course was medically necessary and appropriate in its entirety. It is my opinion that care was reasonable and necessary through approximately visit 20 (10/23/2025), beyond which point continued unmodified care is not supported, for the reasons set forth in Section VIII.

Question 2:

Does the duration and frequency of chiropractic care provided in this case (35 sessions over 4 months) fall within a reasonable range for an auto-related neck/back/soft tissue injury episode, based on current evidence-based guidelines and typical chiropractic practice? If not, at approximately what date or visit range would you say treatment reasonably changed character?

See Section VIII.A. The 35-session/4-month course exceeds the 6–12 visit / 2–4 week guideline benchmark for an initial therapeutic trial, and exceeds (roughly doubles) the Oklahoma workers’ compensation 60-day/18-visit comparator cited for context in Section VIII.C. Based on the chart’s own symptom-plateau data, treatment reasonably changed in character at approximately visit 20 (10/23/2025), at which point the guideline-consistent approach would have been reassessment, tapering, or referral rather than continued unmodified care.

Question 3:

*Were the chiropractic procedures and modalities utilized (manipulation, modalities, exercises, etc.) appropriate for the documented diagnoses and exam findings, or do any appear excessive, duplicative, or not medically necessary? Please specifically speak to 'Alpha **Stim microcurrent** therapy which was provided to reduce the headaches and dizziness.'*

See Section IX for the full modality-specific analysis. Chiropractic manipulation (98940) was performed consistent with typical protocol throughout. Myofascial release, muscle stimulation, and ultrasound were rotated across visits in a manner generally consistent

Question 4:

See Sections IV.A (mechanism), IV.B (ER diagnostic findings), and VII (causation analysis) for full discussion. In summary: the claimant sustained a rear-end MVC on 8/23/2025; diagnoses assigned were consistent with cervical, thoracic, and lumbar soft-tissue strain/sprain, headache, and left-shoulder/hip pain; ER imaging identified pre-existing multilevel cervical degenerative disease (C3-4, C5-6, C6-7) and the claimant's own history disclosed a pre-existing, independently-managed chronic headache condition under work-up by an outside neurologist and allergist.

Does medical documentation and/or your examination support a causal relationship between the claimed accident and the symptoms presented or injury(s) claimed?

Question 6:

See Sections VIII.A–VIII.B. Ongoing chiropractic care is not supported as reasonable, medically necessary, or causally related to this accident on the current record. The claimant’s own charted symptom ratings reached a stable plateau by approximately visit 20 (10/23/2025), and no objective finding was re-measured at any point after the 8/29/2025 intake to establish a continuing functional deficit. Accordingly, no ongoing chiropractic treatment beyond what is already reflected in this file is supported.

25 of 29

As set forth in the response to Question 6, ongoing chiropractic treatment is not supported as reasonable and necessary on this record; accordingly, no opinion is offered on frequency or duration of further chiropractic care. With respect to expectation of return to pre-accident status: the claimant's own charted pain ratings never returned to zero at any point across the 35-visit course, and given the pre-existing cervical degenerative disease and aggravation finding discussed in Section VII.C, a full return to a pre-accident asymptomatic baseline is not an appropriate expectation for the cervical spine specifically. The thoracic, lumbar, shoulder, and hip complaints, representing new soft-tissue injury without documented pre-existing pathology, would be expected to fully resolve within standard soft-tissue healing timeframes.

Please document all medical records reviewed to include provider, specialty, dates of service, and if applicable findings of the physical exam performed.

XII. Impairment Rating (AMA Guides, 6th Edition)

XIII. Summary of Opinions

- 26 of 29

2. Causal apportionment of the headache and dizziness complaints cannot be completed on the current record, given the claimant's pre-existing, independently-managed outside neurology/allergy work-up for chronic headaches; this opinion is offered on an interim basis. (Section VII.E)
3. The course of chiropractic care was reasonable and necessary through approximately visit 20 (10/23/2025), reflecting a guideline-consistent initial therapeutic trial and continued care during a period of documented, if gradual, subjective improvement. (Section VIII.A)
4. Continued, unmodified chiropractic care beyond approximately visit 20 (10/23/2025) is difficult to support as reasonable and necessary, in the absence of any documented reassessment, objective re-measurement, plan modification, or referral, notwithstanding a therapeutically stable plateau reflected in the claimant's own charted pain ratings. This opinion concerns duration and the absence of reassessment, not the manipulative technique itself, which was performed consistently with accepted practice throughout. (Sections VIII.A–VIII.B)
5. Alpha-Stim/MENS therapy was introduced on 9/24/2025 without any documented differentiation between a cervicogenic mechanism and the claimant's pre-existing neurological/allergy-related headache condition, and its continuation for 24 consecutive visits, without interval reassessment or that threshold differentiation ever being made, is not supported as reasonable and necessary. (Section IX.B)
6. Ongoing chiropractic care is not supported as reasonable, medically necessary, or causally related to this accident on the current record; no further chiropractic treatment beyond what is already reflected in this file is indicated. Full return to a pre-accident asymptomatic baseline is not an appropriate expectation for the cervical spine given the pre-existing degenerative disease and aggravation finding addressed in Section VII.C, though the thoracic, lumbar, shoulder, and hip complaints would be expected to fully resolve. (Section XI, Questions 6–7)

XIV. Limitations, Disclosures, and Certification

- I certify that the clinical findings, opinions, and conclusions expressed in this report reflect my own independent professional judgment, based on my training, experience, and personal review of the records identified in Section II. No artificial intelligence tool was used to generate, determine, or formulate my medical opinions.

- The opinions expressed herein represent my professional medical judgment based on the records made available to me as of the date of this report. Should additional records become available — including but not limited to prior neurological or allergy/immunology records, baseline imaging, or other documentation not currently in my possession — I reserve the right to review such records and amend, supplement, or modify my opinions as appropriate.
- I have no financial interest in the outcome of this claim beyond my usual and customary compensation for this record review.
- This report is a records-only peer review; no doctor-patient relationship was established, and I had no direct interaction with the claimant.
- The opinions expressed are the independent opinions of the undersigned, are not influenced by the referral source or the outcome of the claim, and are held to a reasonable degree of medical probability unless otherwise stated.

Leslie Welch, D.C., CICE, NRCME

License number / state: Oklahoma State Board of Chiropractic Examiners, License #3361

Date signed: 8/5/2026

Appendix C — Cited Literature

- Globe G, Farabaugh RJ, Hawk C, Morris CE, Baker G, Whalen WM, Walters S, Kaeser M, Dehen M, Augat T. Clinical Practice Guideline: Chiropractic Care for Low Back Pain. J Manipulative Physiol Ther. 2016;39(1):1-22.
doi:10.1016/j.jmpt.2015.10.006. (Establishes the 6-12 visit/2-4 week initial therapeutic trial framework, interim reassessment expectation, and trial-of-therapeutic-withdrawal concept upon reaching maximum therapeutic improvement.)
- Whalen WM, Hawk C, Farabaugh RJ, Daniels CJ, Taylor DN, Anderson KR, Crivelli LS, Anderson DR, Thomson LM, Sarnat RL. Best Practices for Chiropractic Management of Adult Patients With Mechanical Low Back Pain: A Clinical Practice Guideline for Chiropractors in the United States. J Manipulative Physiol Ther. 2023.
doi:10.1016/j.jmpt.2023.04.010. (2023 update to the above.)
- Whalen W, Farabaugh RJ, Hawk C, Minkalis AL, Lauretti W, Crivelli LS, Wyatt L, Sheppard M, Walters SA. Best-Practice Recommendations for Chiropractic Management of Patients With Neck Pain. J Manipulative Physiol Ther. 2019 (epub ahead of print). (Directly on point for this claimant's cervicalgia: recommends an initial trial of 6-12 visits over 2-4 weeks, additional 6-visit trials only with demonstrated clinically meaningful improvement, and describes interim assessment, trials of therapeutic withdrawal, and MMI determination as the

guideline-consistent response once a plateau is reached. Also addresses LLLT and IFC as passive-modality adjuncts.)

- Bryans R, Decina P, Descarreaux M, Duranleau M, Marcoux H, Potter B, Ruegg RP, Shaw L, Watkin R, White E. Evidence-based guidelines for the chiropractic treatment of adults with neck pain. *J Manipulative Physiol Ther.* 2014;37(1):42-63. doi:10.1016/j.jmpt.2013.08.010.
- Bussi res AE, Stewart G, Al-Zoubi F, et al. The treatment of neck pain-associated disorders and whiplash-associated disorders: a clinical practice guideline. *J Manipulative Physiol Ther.* 2016;39:523-564.e27. doi:10.1016/j.jmpt.2016.08.007. (Most directly applicable given this claimant’s whiplash-mechanism MVC.)
- Myhrvold BL, V llestad NK, Irgens P, Robinson HS, Ax n I. Clinical indicators for recommending continued care to patients with neck pain in chiropractic practice: a cohort study. *Chiropr Man Therap.* 2023;31(1):30. doi:10.1186/s12998-023-00507-y. (Supports a 4-week reassessment point for neck pain as the point at which continued-care decisions are made based on clinical indicators, not a default visit count.)
- Dynamic Chiropractic. “The ACOEM Occupational Medicine Practice Guidelines: Biased Against Chiropractic Care.” dynamicchiropractic.com/article/50013. (Cited in Section VI regarding the ACOEM “optional” classification caveat.)